Danaher Corp. (DHR) News
Filter DHR News Items
DHR News Results
|Loading, please wait...|
DHR News Highlights
- DHR's 30 day story count now stands at 58.
- Over the past 24 days, the trend for DHR's stories per day has been choppy and unclear. It has oscillated between 1 and 11.
- The most mentioned tickers in articles about DHR are CRC, UBS and DH.
Latest DHR News From Around the Web
Below are the latest news stories about Danaher Corp that investors may wish to consider to help them evaluate DHR as an investment opportunity.
Danaher Corporation (NYSE:DHR) declares $0.25/share quarterly dividend, 19.0% increase from prior dividend of $0.21.Forward yield 0.38%Payable April 29; for shareholders of record March 25;
Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.25 per share of its common stock, payable on April 29, 2022 to holders of record on March 25, 2022. In addition, the Board of Directors has approved a quarterly cash dividend of $11.875 per share of its 4.75% Series A Mandatory Convertible Preferred Stock, payable on April 15, 2022 to holders of record on March 31, 2022. The Board of Directors has also approved a quart
Global Laboratory Consumables Market Report, Featuring Profiles of Key Players Including Agilent, Beckman Coulter, Bio-Rad, PerkinElmer, Roche and Shimadzu
DUBLIN , Feb. 18, 2022 /PRNewswire/ -- The "Global Laboratory Consumables Market 2021" report has been added to ResearchAndMarkets.com''s offering. The Global Laboratory Consumables Market report is designed for general management, product managers and marketing executives in the laboratory consumables industry. For them, it provides up-to-date market data about those technologies in their areas of interest. and related markets. Information on specific segments or the whole industry can be used to evaluate markets, the competitive landscape, or identify opportunities and acquisition targets. A strategy for the consumables market must involve geographic market composition, market growth rate, and new competitors. This report saves time by providing comprehensive data in an easily readabl...
Despite some impressive recent quarters, Hologic (HOLX) shares have underperformed since my last update on this diversified diagnostics and women’s health company. Hologic has benefited from an unexpectedly strong “tail” to COVID-19 testing revenue, but underlying performance has been solid as well, and the company is now in a much...
Danaher (NYSE: DHR ) has outperformed the market over the past 10 years by 8.65% on an annualized basis. Buying $1,000 In DHR: 10 years ago, an investor could have purchased 24.79 shares of Danaher at the time with $1,000. This investment in DHR would have produced an average … Full story available on Benzinga.com
General Electric (GE) decides to reshape its steam power portfolio by divesting certain businesses to the EDF Group. It expects to record non-cash charges related to the deal.
Rating Action: Moody's affirms Danaher at Baa1; revises outlook to positiveGlobal Credit Research - 10 Feb 2022New York, February 10, 2022 -- Moody's Investors Service ("Moody's") affirmed the ratings of Danaher Corporation and certain related entities (collectively referred to as "Danaher"), including the Baa1 senior unsecured ratings and Prime-2 short term commercial paper ratings. At the same time, social considerations including the company's response in commercializing various products related to the COVID-19 pandemic, is driving enhanced performance and cash flow, contributing to the outlook change to positive.Ratings affirmed:..Issuer: Danaher Corporation.Senior unsecured rating at Baa1.Commercial paper rating at Prime-2..Issuer: DH Europe Finance II S.a.r.l..Backed senior unsec...
Bethesda, MD, based Investment company Profund Advisors Llc (Current Portfolio) buys Danaher Corp, Lucid Group Inc, Fortinet Inc, West Pharmaceutical Services Inc, Palo Alto Networks Inc, sells Tesla Inc, American Tower Corp, Prologis Inc, Crown Castle International Corp, Equinix Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Profund Advisors Llc.
Danaher's (DHR -0.1%) recent underperformance is a reason to buy shares, according to UBS, who has added the stock to its list of Pricing Power Standouts. Through Friday's close, Danaher shares are down 12.6% year to date. The firm said that even though it expects inflation to moderate further into the year,...
Danaher''s recent underperformance is a reason to buy shares, according to UBS, who has added the stock to its list of Pricing Power Standouts.